Conference Coverage

VIDEO: PCPs fuzzy on HCC surveillance in cirrhosis


 

AT DDW 2014

CHICAGO – Several medical societies recommend that patients with cirrhosis undergo ultrasound surveillance for hepatocellular carcinoma every 6 months, but studies suggest less than 20% receive surveillance. The most common reason for failure to get the screening is lack of provider recommendation.

In a video interview with us at the annual Digestive Disease Week, Dr. Eimile Dalton-Fitzgerald of the University of Texas Southwestern Medical Center at Dallas delves into primary care provider (PCP) practice patterns, knowledge, and attitudes regarding hepatocellular carcinoma (HCC) surveillance gleaned from a survey of 77 PCPs in a large safety-net hospital in Dallas County, Texas.

Though most PCPs surveyed believe HCC surveillance is their responsibility (90%) and is effective for early tumor detection in cirrhosis (85%), many had misconceptions about the appropriate surveillance test choice.

PCPs also report several barriers to HCC surveillance, including not being up to date with surveillance guidelines (68%), difficulty with patient communication (56%), and having more important issues to manage in the clinic (52%).

A full 87% also said they’re influenced by a lack of recommendations from the U.S. Preventive Services Task Force, which has yet to weigh in on the issue.

Dr. Dalton-Fitzgerald reported no conflicting interests.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

pwendling@frontlinemedcom.com

Recommended Reading

VIDEO: When to screen for celiac disease in hypothyroidism
MDedge Internal Medicine
Moderate wine intake may benefit kidneys, curb heart disease risk
MDedge Internal Medicine
Interferon-free regimen improves response in HCV
MDedge Internal Medicine
VIDEO – IBD meds found safe during pregnancy
MDedge Internal Medicine
Expanded cytoreduction criteria improved survival of carcinoid liver metastases
MDedge Internal Medicine
VIDEO: ‘Three D’ for hepatitis C called ‘revolutionary’
MDedge Internal Medicine
VIDEO: Oral drugs tackle hepatitis C genotypes 2, 3
MDedge Internal Medicine
VIDEO: Oral drugs replacing interferon for hepatitis C
MDedge Internal Medicine
RM-131 makes headway against diabetic gastroparesis
MDedge Internal Medicine
VIDEO: GERD may increase heart attack risk
MDedge Internal Medicine